Patents by Inventor Jeno Gyuris

Jeno Gyuris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
    Patent number: 11897948
    Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 13, 2024
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Jeno Gyuris, Lorena Lerner
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20230365710
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/IER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 16, 2023
    Inventors: Sylvie VINCENT, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT
    Publication number: 20230295285
    Abstract: Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one GDF15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one GDF15 modulator.
    Type: Application
    Filed: September 7, 2022
    Publication date: September 21, 2023
    Inventors: Jeno Gyuris, Lorena Lerner, Jie Lin
  • Anti-GDF-15 antibodies
    Patent number: 11725047
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: August 15, 2023
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 11680108
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: June 20, 2023
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • MONOCLONAL ANTIBODIES TARGETING HSP70 AND THERAPEUTIC USES THEREOF
    Publication number: 20230128075
    Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Asylia Therapeutics
    Inventors: Robert Z. ORLOWSKI, Richard J. JONES, Laura C. BOVER, Jeno GYURIS, John MILLER, James Bernard McCLORY, Darragh MAC CANN, William M. WINSTON, SR.
  • TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR
    Publication number: 20220403015
    Abstract: The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.
    Type: Application
    Filed: February 2, 2022
    Publication date: December 22, 2022
    Inventors: Jeno Gyuris, Lorena Lerner
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20210171627
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: August 13, 2020
    Publication date: June 10, 2021
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • ANTI-GDF-15 ANTIBODIES
    Publication number: 20210101968
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: March 19, 2020
    Publication date: April 8, 2021
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, JR., Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20200299406
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-NOTCH3 antibodies
    Patent number: 10745476
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: August 18, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • Anti-GDF15 antibodies
    Patent number: 10597444
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 24, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Anti-ERBB3 antibodies
    Patent number: 10494441
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 3, 2019
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR
    Publication number: 20190292251
    Abstract: The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.
    Type: Application
    Filed: November 1, 2018
    Publication date: September 26, 2019
    Inventors: Jeno Gyuris, Lorena Lerner
  • METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT
    Publication number: 20190292253
    Abstract: Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one GDF15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one GDF15 modulator.
    Type: Application
    Filed: November 2, 2018
    Publication date: September 26, 2019
    Inventors: Jeno Gyuris, Lorena Lerner, Jie Lin
  • TREATMENT OF CHRONIC KIDNEY DISEASE AND OTHER RENAL DYSFUNCTION USING A GDF15 MODULATOR
    Publication number: 20190292252
    Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
    Type: Application
    Filed: November 2, 2018
    Publication date: September 26, 2019
    Inventors: Jeno Gyuris, Lorena Lerner
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20180230213
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 16, 2018
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, JR., Jeno Gyuris
  • PREDICTING TUMOR RESPONSE TO ANTI-ERBB3 ANTIBODIES
    Publication number: 20180195120
    Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.
    Type: Application
    Filed: November 27, 2017
    Publication date: July 12, 2018
    Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris
  • ANTI-GDF15 ANTIBODIES
    Publication number: 20180142013
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: July 20, 2017
    Publication date: May 24, 2018
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20180030149
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 1, 2018
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris